SI1674111T1 - Protitelo proti glipikanu 3 - Google Patents

Protitelo proti glipikanu 3

Info

Publication number
SI1674111T1
SI1674111T1 SI200531212T SI200531212T SI1674111T1 SI 1674111 T1 SI1674111 T1 SI 1674111T1 SI 200531212 T SI200531212 T SI 200531212T SI 200531212 T SI200531212 T SI 200531212T SI 1674111 T1 SI1674111 T1 SI 1674111T1
Authority
SI
Slovenia
Prior art keywords
antibody
glypican
disclosed
agent
cancers
Prior art date
Application number
SI200531212T
Other languages
English (en)
Inventor
Kiyotaka Nakano
Takeshi Yoshino
Jun-Ichi Nezu
Hiroyuki Tsunoda
Tomoyuki Igawa
Hiroko Konishi
Megumi Tanaka
Izumi Sugo
Shigeto Kawai
Takahiro Ishiguro
Yasuko Kinoshita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784028&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1674111(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SI1674111T1 publication Critical patent/SI1674111T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200531212T 2004-07-09 2005-07-08 Protitelo proti glipikanu 3 SI1674111T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004203637 2004-07-09
EP05760156A EP1674111B1 (en) 2004-07-09 2005-07-08 Anti-glypican 3 antibody
PCT/JP2005/013103 WO2006006693A1 (ja) 2004-07-09 2005-07-08 抗グリピカン３抗体

Publications (1)

Publication Number Publication Date
SI1674111T1 true SI1674111T1 (sl) 2011-02-28

Family

ID=35784028

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531212T SI1674111T1 (sl) 2004-07-09 2005-07-08 Protitelo proti glipikanu 3

Country Status (26)

Country Link
US (3) US7919086B2 (sl)
EP (4) EP2314317A3 (sl)
JP (3) JP4011100B2 (sl)
KR (2) KR101300545B1 (sl)
CN (4) CN111925445A (sl)
AT (1) ATE486610T1 (sl)
AU (1) AU2005256113B2 (sl)
BR (1) BRPI0506125B8 (sl)
CA (1) CA2544692C (sl)
CY (1) CY1111649T1 (sl)
DE (1) DE602005024502D1 (sl)
DK (1) DK1674111T3 (sl)
ES (1) ES2353967T3 (sl)
HK (1) HK1092161A1 (sl)
IL (1) IL172938A (sl)
MX (1) MXPA06002890A (sl)
MY (1) MY145073A (sl)
NO (1) NO343105B1 (sl)
NZ (2) NZ545720A (sl)
PL (1) PL1674111T3 (sl)
PT (1) PT1674111E (sl)
RU (2) RU2427588C2 (sl)
SI (1) SI1674111T1 (sl)
TW (1) TWI455946B (sl)
UA (1) UA94019C2 (sl)
WO (1) WO2006006693A1 (sl)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
ATE486610T1 (de) * 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
PT1800693E (pt) 2004-08-24 2013-08-23 Chugai Pharmaceutical Co Ltd Terapia adjuvante utilizando anticorpo antiglipicana
CN101068836B (zh) * 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
NZ569697A (en) * 2006-01-20 2012-01-12 Women S & Children S Health Res Inst Method of treatment, prophylaxis and diagnosis of pathologies of the bone by the modulation of GPC3
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP2228450A1 (en) * 2006-04-13 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
US20100233759A1 (en) 2007-03-15 2010-09-16 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
CN101663391A (zh) 2007-04-26 2010-03-03 中外制药株式会社 使用含高浓度氨基酸的培养基的细胞培养方法
PT2178921E (pt) 2007-07-17 2016-03-23 Squibb & Sons Llc Anticorpos monoclonais contra glipicano-3
DK2186905T3 (en) * 2007-08-07 2016-09-19 Chugai Pharmaceutical Co Ltd Method of Preparation of Heterogeneous Protein
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP2584043A3 (en) * 2007-09-28 2013-10-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having improved kinetics in plasma
WO2009051108A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
US9802993B2 (en) 2007-10-15 2017-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate
JP5337044B2 (ja) * 2007-10-24 2013-11-06 中外製薬株式会社 異種タンパク質製造のための細胞及びそれを用いた製造方法
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TW200949248A (en) * 2008-03-17 2009-12-01 Univ Miyazaki Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
HUE054712T2 (hu) 2008-07-08 2021-09-28 Geneuro Sa Specifikus ligandum terápiás alkalmazása MSRV-vel összefüggõ betegségekben
WO2010050448A1 (ja) 2008-10-28 2010-05-06 中外製薬株式会社 ペプチド含有動物細胞培養用培地
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
WO2010083463A1 (en) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
JP5715050B2 (ja) 2009-04-22 2015-05-07 中外製薬株式会社 異種タンパク質を高生産する細胞の作製方法
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
JP5051806B2 (ja) * 2009-08-07 2012-10-17 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
WO2011038159A2 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103221427B (zh) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 抗ox40抗体和使用其的方法
BR112013005145B1 (pt) 2010-09-02 2022-02-15 Vaccinex, Inc Anticorpo isolado ou seu fragmento de ligação ao antígeno que se liga especificamente ao cxcl13, composição e uso de uma composição
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR101903208B1 (ko) 2010-12-28 2018-10-01 추가이 세이야쿠 가부시키가이샤 동물 세포의 배양 방법
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
DK2698431T3 (da) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
US11028149B2 (en) 2011-04-01 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Recombinant polypeptide production method
WO2012145469A1 (en) * 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
CN110680920A (zh) 2011-09-30 2020-01-14 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
KR20140076593A (ko) 2011-09-30 2014-06-20 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
CA2853230C (en) 2011-10-31 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP2809683B1 (en) * 2012-01-31 2018-10-03 SBI Biotech Co., Ltd. Anti-phospholipase d4 antibody
SG11201405137QA (en) 2012-02-24 2014-12-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
CA2865928C (en) 2012-03-02 2021-02-16 Vaccinex, Inc. Cxcl13 antagonist for the treatment of sjogren's syndrome
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
AU2013268418B2 (en) 2012-05-30 2017-12-07 Chugai Seiyaku Kabushiki Kaisha Target-tissue-specific antigen-binding molecule
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
SG11201502801RA (en) 2012-10-10 2015-06-29 Chugai Pharmaceutical Co Ltd Method for establishing modified host cell
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
WO2015097928A1 (ja) 2013-12-24 2015-07-02 中外製薬株式会社 可溶性ｇｐｃ３タンパク質の測定方法
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2014121053A1 (en) 2013-01-31 2014-08-07 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US20160000946A1 (en) * 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
CN107460201A (zh) 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
RU2758952C1 (ru) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
WO2015083764A1 (ja) 2013-12-04 2015-06-11 中外製薬株式会社 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
CN106459959A (zh) * 2014-05-08 2017-02-22 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
TW201623333A (zh) 2014-05-13 2016-07-01 Chugai Pharmaceutical Co Ltd 對具有免疫抑制機能之細胞的ｔ細胞重定向抗原結合分子
WO2015172341A1 (zh) * 2014-05-14 2015-11-19 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
WO2016036973A1 (en) * 2014-09-04 2016-03-10 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
MX358243B (es) * 2014-09-16 2018-08-10 Ovascience Inc Anticuerpos anti-vasa y metodos de produccion y uso de los mismos.
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
CA2973771A1 (en) * 2015-01-16 2016-07-21 Minomic International Ltd. Glypican epitopes and uses thereof
CN104610441B (zh) * 2015-03-04 2018-02-13 首都医科大学 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
DK3333192T3 (da) * 2015-08-03 2021-05-31 Cafa Therapeutics Ltd Antistof imod glypican-3 og anvendelse deraf
CN105112046A (zh) * 2015-09-29 2015-12-02 南通大学 核壳结构量子点的制备方法、靶向肿瘤标志物gpc-3的荧光纳米探针及其制备方法
CN105126123B (zh) * 2015-09-29 2018-04-03 南通大学 纳米探针的制备方法、基于天然产物单体和纳米探针的纳米药物的制备方法及应用
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
CN108738347B (zh) * 2016-03-10 2022-01-14 国立癌症研究中心 辅助肝细胞癌患者的再发风险预测的方法、装置、计算机程序制品及试剂盒
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
JP6887613B2 (ja) * 2016-03-31 2021-06-16 国立大学法人東北大学 がん微小環境を標的とした抗ポドカリキシン抗体
KR102529012B1 (ko) 2016-04-22 2023-05-09 크라제 메디컬 씨오 리미티드 세포성 면역요법을 위한 조성물 및 방법
JP2019530431A (ja) 2016-07-26 2019-10-24 テッサ・セラピューティクス・プライベート・リミテッド キメラ抗原受容体
JP7125347B2 (ja) 2016-08-22 2022-08-24 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CN110214151A (zh) 2016-11-28 2019-09-06 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
JP2018093823A (ja) 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
WO2018129261A1 (en) * 2017-01-05 2018-07-12 Brown University Methods and compositions relating to anti-chi3l1 antibody reagents
IL300270A (en) 2017-01-10 2023-04-01 Univ Yamaguchi Anti-GPC3 antibody
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
AU2018258049A1 (en) * 2017-04-26 2019-12-12 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2018235855A1 (ja) * 2017-06-20 2018-12-27 国立大学法人東京医科歯科大学 抗硫酸化グリコサミノグリカン抗体
EP3658185A4 (en) 2017-07-28 2021-07-14 Phanes Therapeutics, Inc. ANTI-TIM-3 ANTIBODIES AND USES THEREOF
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
US20210206845A1 (en) 2017-11-28 2021-07-08 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
KR20210010996A (ko) 2018-05-21 2021-01-29 추가이 세이야쿠 가부시키가이샤 유리 용기에 봉입된 동결건조 제제
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha FILLING NOZZLE
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
EP3825404A4 (en) 2018-07-17 2022-04-13 Noile-Immune Biotech, Inc. CAR CONTAINING ANTI-GPC3 SINGLE STRAND ANTIBODY
CN110760005A (zh) * 2018-07-25 2020-02-07 上海细胞治疗集团有限公司 一种靶向Glypican-3抗原的嵌合抗原受体修饰T细胞及其用途
EA202190915A1 (ru) 2018-10-01 2021-08-17 Эдисет Био, Инк. Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения солидных опухолей
AU2019366956A1 (en) 2018-10-23 2021-05-20 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
CN113891897A (zh) * 2019-03-21 2022-01-04 新加坡科技研究局 组合物
TW202108625A (zh) 2019-05-15 2021-03-01 日商協和麒麟股份有限公司 與cd40及gpc3結合之雙專一性抗體
EP4023230A4 (en) 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha ANTIBODY CLEAVAGE SITE BINDING MOLECULE
WO2020246567A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド
US20220259298A1 (en) * 2019-07-12 2022-08-18 Kyoto University Neutralizing Antibody for Tooth Regeneration Treatment Targeting USAG-1 Molecule
AU2020319874A1 (en) * 2019-08-01 2022-03-17 R.P. Scherer Technologies, Llc Antibody specific for GPC3 and methods of use thereof
CN112390886B (zh) * 2019-08-16 2022-08-16 原启生物科技(上海)有限责任公司 一种分离的抗原结合蛋白及其用途
CN113227148B (zh) * 2019-12-05 2022-11-01 上海翰森生物医药科技有限公司 抗gpc3抗体、其抗原结合片段及其医药用途
CN111116749B (zh) * 2019-12-31 2023-02-17 南京拂晓生物科技有限公司 重组的人源化gpc3抗体及其制备和应用
MX2022013112A (es) 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
CN111909902B (zh) * 2020-06-24 2021-12-21 天津金虹生物科技开发有限公司 一种杂交瘤细胞株、单克隆抗体及其制备方法和应用、制备致敏胶乳原液的方法以及试剂盒
KR20230048059A (ko) 2020-07-31 2023-04-10 추가이 세이야쿠 가부시키가이샤 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
AU2021343594A1 (en) 2020-09-17 2023-05-11 Shanghai Lyn-Crest Enterprise Management Co., Ltd. Bispecific recombinant protein and use thereof
CN114478780A (zh) * 2020-10-23 2022-05-13 华中农业大学 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
KR20220080381A (ko) * 2020-12-07 2022-06-14 (주)이노베이션바이오 Gpc3에 특이적인 항체 및 이의 용도
CN112608907B (zh) * 2020-12-18 2023-01-17 十堰市太和医院（湖北医药学院附属医院） 磷脂酰肌醇蛋白聚糖3单克隆抗体，杂交瘤细胞株和应用
IL303783A (en) * 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising single immunoglobulin variable sites targeting GLYPICAN-3 and the T-cell receptor
US20240076412A1 (en) * 2021-01-05 2024-03-07 National Institute Of Biological Sciences, Beijing A bispecific antibody targeting gpc3 and cd47
WO2022166876A1 (zh) * 2021-02-03 2022-08-11 江苏先声药业有限公司 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
CN117615786A (zh) * 2021-05-07 2024-02-27 森蒂生物科学公司 嵌合抗原受体及其使用方法
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
CN113248616B (zh) * 2021-07-07 2022-04-12 北京艺妙神州医药科技有限公司 靶向gpc3的嵌合抗原受体及其用途
EP4367141A1 (en) * 2021-07-07 2024-05-15 Triumvira Immunologics USA, Inc. Gpc3 t cell-antigen couplers and uses thereof
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
AU2022326107A1 (en) 2021-08-12 2024-03-14 Shanghai Ttm-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
WO2023034762A2 (en) * 2021-08-30 2023-03-09 Obi Pharma, Inc. Bispecific dendritic cell engager and uses thereof
WO2023030539A1 (en) * 2021-09-06 2023-03-09 Nanjing Legend Biotech Co., Ltd. Anti-gpc3 chimeric antigen receptor and methods of use thereof
WO2023058705A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体の製剤
KR20230060546A (ko) 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
CA3237201A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
CA3238167A1 (en) * 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same
WO2024076375A1 (en) * 2022-10-07 2024-04-11 Jecho Laboratories, Inc. Glypican 3 antibody and related methods
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
CN116333172B (zh) * 2023-05-04 2024-02-09 广州百暨基因科技有限公司 融合蛋白及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
AU3272695A (en) * 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
EP1020522B1 (en) * 1997-10-03 2007-09-19 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
MXPA03002161A (es) 2000-09-12 2006-03-21 Union Carbide Chem Plastic Compuestos de polimeros que contienen copolimeros de oxido de alquileno.
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
US20020194747A1 (en) * 2001-06-21 2002-12-26 Passke Joel L. Footwear with bladder filter
DE60228721D1 (en) 2001-06-22 2008-10-16 Chugai Pharmaceutical Co Ltd Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
AU2002339845B2 (en) * 2001-08-03 2009-03-26 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
EP1462799B1 (en) 2001-11-14 2011-01-19 Kabushiki Kaisha Toshiba Ultrasonograph with calculation of ultrasonic wave refraction
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
CN100401068C (zh) * 2002-05-23 2008-07-09 阳光溪流女子学院健康科学中心 肝细胞癌的诊断
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004023145A1 (ja) * 2002-09-04 2004-03-18 Perseus Proteomics Inc. Ｇｐｃ3の検出による癌の診断方法
JP4090345B2 (ja) 2002-12-24 2008-05-28 株式会社グラノプト 液相結晶成長法
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
ATE486610T1 (de) 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
PT1800693E (pt) 2004-08-24 2013-08-23 Chugai Pharmaceutical Co Ltd Terapia adjuvante utilizando anticorpo antiglipicana
CN101068836B (zh) 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) * 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
TW200949248A (en) * 2008-03-17 2009-12-01 Univ Miyazaki Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
EP1674111A1 (en) 2006-06-28
RU2611751C2 (ru) 2017-02-28
TWI455946B (zh) 2014-10-11
EP1674111A4 (en) 2008-03-19
MXPA06002890A (es) 2006-06-05
EP2314317A2 (en) 2011-04-27
ATE486610T1 (de) 2010-11-15
NZ579543A (en) 2011-07-29
EP2314317A3 (en) 2011-06-29
CN111925445A (zh) 2020-11-13
US20150259417A1 (en) 2015-09-17
KR20070034448A (ko) 2007-03-28
CA2544692C (en) 2014-04-01
US7919086B2 (en) 2011-04-05
CN1842540B (zh) 2012-07-04
BRPI0506125B1 (pt) 2019-10-15
MY145073A (en) 2011-12-15
JP2009232848A (ja) 2009-10-15
UA94019C2 (ru) 2011-04-11
KR101413402B1 (ko) 2014-06-27
EP2216046B1 (en) 2014-03-12
CN102702353A (zh) 2012-10-03
PL1674111T3 (pl) 2011-04-29
EP2216046A3 (en) 2010-12-22
RU2006104842A (ru) 2007-08-27
EP2898897A3 (en) 2015-10-14
AU2005256113A8 (en) 2008-09-11
KR101300545B1 (ko) 2013-09-02
EP1674111B1 (en) 2010-11-03
AU2005256113B2 (en) 2011-02-10
DK1674111T3 (da) 2011-02-07
RU2011115845A (ru) 2012-10-27
CY1111649T1 (el) 2015-10-07
US20070190599A1 (en) 2007-08-16
JP4011100B2 (ja) 2007-11-21
BRPI0506125B8 (pt) 2021-05-25
WO2006006693A1 (ja) 2006-01-19
CA2544692A1 (en) 2006-01-19
PT1674111E (pt) 2010-12-15
RU2427588C2 (ru) 2011-08-27
CN1842540A (zh) 2006-10-04
AU2005256113A1 (en) 2006-03-30
DE602005024502D1 (de) 2010-12-16
EP2898897A2 (en) 2015-07-29
TW200617022A (en) 2006-06-01
HK1092161A1 (en) 2007-02-02
JP2013039131A (ja) 2013-02-28
BRPI0506125A (pt) 2006-10-24
EP2216046A2 (en) 2010-08-11
NO20063539L (no) 2007-01-09
US20100248359A1 (en) 2010-09-30
IL172938A0 (en) 2006-06-11
NZ545720A (en) 2010-01-29
NO343105B1 (no) 2018-11-05
IL172938A (en) 2013-09-30
JP5715603B2 (ja) 2015-05-07
KR20130014698A (ko) 2013-02-08
JPWO2006006693A1 (ja) 2008-05-01
ES2353967T3 (es) 2011-03-08
CN105820249A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
HK1092161A1 (en) Anti-glypican 3 antibody
ATE516842T1 (de) Intravasculärer führungsdraht
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
EP2620450A3 (en) Anti-CTLA-4 antibody compositions
EP1553975B8 (en) Optimized fc variants and methods for their generation
WO2004099249A3 (en) Optimized fc variants and methods for their generation
MX2009004170A (es) Materiales y metodos para inmunoglicoproteinas mejoradas.
EP2000541A4 (en) HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
MY150643A (en) Methods and compositions for targeting hepsin
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
NO20082852L (no) Faramsoytisk blanding samt bruk av alfa-hydroksy karbonylforbindelser som reduksjonsmidler
WO2007143004A3 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
WO2007002096A3 (en) Methods and compositions for targeting ifnar2
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
EP2126055A4 (en) BY HYBRIDOMA CELL LINE AR51A630.3 PRODUCED TUMOR MODIFYING ANTIBODY 010207-01
白岩孝行 et al. The Amur Okhotsk Project
UA93875C2 (ru) Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125)
ITTO20020129V0 (it) Aletta parasole per veicoli.
ZA200301901B (en) Fuel additive.
AP2006003532A0 (en) Anti-VEGF antibodies.
WO2006017545A3 (en) Systems and methods for inhibiting metastasis
TW200719384A (en) Lamp with protective layer and process for producing a lamp of this type